Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis

Molecular Medicine Reports

Volumn 11, Issue 4, 2015, Pages 2831-2837

  Shen, Qinqin ^a   Chen, Bing ^b   Xiao, Zhifeng ^b   Zhao, Lifen ^a   Xu, Xuefeng ^a   Wan, Xuan ^a   Jin, Mulan ^c   Dai, Jianwu ^b   Dai, Huaping ^a  

^a Department of Respiratory and Critical Care Medicine ^*  (China)

^b INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Conditioned medium; Lung fibrosis; Mesenchymal stem cells; Paracrine

Indexed keywords

BETA1 INTEGRIN; BLEOMYCIN; COLLAGEN; HERMES ANTIGEN; HYDROXYPROLINE; CULTURE MEDIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; LUNG INJURY; MESENCHYMAL STEM CELL; NICK END LABELING; NONHUMAN; PARACRINE SIGNALING; PNEUMONIA; RAT; ANIMAL; CHEMICALLY INDUCED; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFECTS; INTESTINE MUCOSA; MALE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHARMACOLOGY; PULMONARY FIBROSIS; TUMOR CELL LINE;

RATTUS;

ANIMALS; APOPTOSIS; BLEOMYCIN; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; HUMANS; INTESTINAL MUCOSA; MALE; MESENCHYMAL STROMAL CELLS; PARACRINE COMMUNICATION; PULMONARY FIBROSIS; RATS;

EID: 84921327929     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.3092     Document Type: Article

References (40)

1. King TE, Jr., Pardo A and Selman M: Idiopathic pulmonary fibrosis. Lancet 378: 1949-1961, 2011.
2. Raghu G, Collard HR, Egan J.J., et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
3. Kropski JA, Lawson WE, Young LR and Blackwell TS: Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech 6: 9-17, 2013.
4. Zoz DF, Lawson WE and Blackwell TS: Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am J Med Sci 341: 435-438, 2011.
5. Hardie WD, Hagood JS, Dave V, et al.: Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle 9: 2769-2776, 2010.
6. Sakai N and Tager AM: Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis. Biochim Biophys Acta 1832: 911-921, 2013.
7. Maher TM, Evans IC, Bottoms S.E., et al.: Diminished prosta-glandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 182: 73-82, 2010.
8. Li X, Shu R, Filippatos G and Uhal BD: Apoptosis in lung injury and remodeling. J Appl Physiol (1985) 97: 1535-1542, 2004.
9. Degryse AL, Tanjore H, Xu X.C., et al.: Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 299: L442-452, 2010.
10. Serrano-Mollar A, Nacher M, Gay-Jordi G, et al.: Intratracheal transplantation of alveolar type II cells reverses bleo-mycin-induced lung fibrosis. Am J Respir Crit Care Med 176: 1261-1268, 2007.
11. Bao S, Wang Y, Sweeney P., et al.: Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 288: L36-L42, 2005.
12. Crestani B, Marchand-Adam S, Quesnel C., et al.: Hepatocyte growth factor and lung fibrosis. Proc Am Thorac Soc 9: 158-163, 2012.
13. Umeda Y, Marui T, Matsuno Y., et al.: Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice. Lab Invest 84: 836-844, 2004.
14. Krause DS, Theise ND, Collector M.I., et al.: Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105: 369-377, 2001.
15. Rejman J, Colombo C and Conese M: Engraftment of bone marrow-derived stem cells to the lung in a model of acute respiratory infection by Pseudomonas aeruginosa. Mol Ther 17: 1257-1265, 2009.
16. Fritzell JA Jr, Mao Q, Gundavarapu S., et al.: Fate and effects of adult bone marrow cells in lungs of normoxic and hyperoxic newborn mice. Am J Respir Cell Mol Biol 40: 575-587, 2009.
17. Tzouvelekis A, Ntolios P and Bouros D: Stem cell treatment for chronic lung diseases. Respiration 85: 179-192, 2013.
18. Conese M, Carbone A, Castellani S and Di Gioia S: Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases. Cells Tissues Organs 197: 445-473, 2013.
19. van Poll D, Parekkadan B, Cho C.H., et al.: Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634-1643, 2008.
20. Xu J, Woods CR, Mora A.L., et al.: Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 293: L131-L141, 2007.
21. van Haaften T, Byrne R, Bonnet S., et al.: Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 180: 1131-1142, 2009.
22. Tögel F, Weiss K, Yang Y., et al.: Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 292: F1626-F1635, 2007.
23. Ashcroft T, Simpson JM and Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470, 1988.
24. Phinney DG: Building a consensus regarding the nature and origin of mesenchymal stem cells. J Cell Biochem Suppl 38: 7-12, 2002.
25. Nauta AJ and Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499-3506, 2007.
26. Lau AN, Goodwin M, Kim CF and Weiss DJ: Stem cells and regenerative medicine in lung biology and diseases. Mol T her 20: 1116-1130, 2012.
27. Sadat S, Gehmert S, Song Y.H., et al.: The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 363: 674-679, 2007.
28. Nakanishi C, Yamagishi M, Yamahara K., et al.: Activation of cardiac progenitor cells through paracrine effects of mesen-chymal stem cells. Biochem Biophys Res Commun 374: 11-16, 2008.
29. Xu YX, Chen L, Wang R., et al.: Mesenchymal stem cell therapy for diabetes through paracrine mechanisms. Med Hypotheses 71: 390-393, 2008.
30. Gazdhar A, Susuri N, Hostettler K., et al.: HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic. PLoS One 8: e65453, 2013.
31. Gazdhar A, Temuri A, Knudsen L., et al.: Targeted gene transfer of hepatocyte growth factor to alveolar type II epithelial cells reduces lung fibrosis in rats. Hum Gene Ther 24: 105-116, 2013.
32. Chakraborty S, Chopra P, Hak A., Dastidar SG and Ray A: Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 22: 499-515, 2013.
33. Sakamoto S, Yazawa T, Baba Y., et al.: Keratinocyte growth factor gene transduction ameliorates pulmonary fibrosis induced by bleomycin in mice. Am J Respir Cell Mol Biol 45: 489-497, 2011.
34. Inghilleri S, Morbini P, Oggionni T., Barni S and Fenoglio C: In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis. Histochem Cell Biol 125: 661-669, 2006.
35. Teixeira KC, Soares FS, Rocha L.G., et al.: Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther 21: 309-316, 2008.
36. Lanza C, Morando S, Voci A., et al.: Neuroprotective mesen-chymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 110: 1674-1684, 2009.
37. Ortiz LA, Gambelli F, McBride C., et al.: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100: 8407-8411, 2003.
38. Kumamoto M, Nishiwaki T, Matsuo N., Kimura H and Matsushima K: Minimally cultured bone marrow mesen-chymal stem cells ameliorate fibrotic lung injury. Eur Respir J 34: 740-748, 2009.
39. Lee SH, Jang AS, Kim Y.E., et al.: Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res 11: 16, 2010.
40. Moodley Y, Atienza D, Manuelpillai U., et al.: Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 175: 303-313, 2009.